Tenaya Therapeutics (TNYA) Cash from Financing Activities (2020 - 2026)
Tenaya Therapeutics' quarterly Cash from Financing Activities came in at -$415000.0 in Q1 2026, down 100.83% year-on-year from $50.3 million in Q1 2025, and down 100.71% quarter-over-quarter from $58.2 million in Q4 2025.
Tenaya Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at -$415000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 100.83% year-over-year to -$415000.0; the trailing twelve-month figure through Mar 2026 stood at $57.7 million (up 12.67% YoY), and the FY2025 full-year result was $108.4 million, up 127.03% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$415000.0, down from $58.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $77.5 million in Q4 2022, with the low at -$501000.0 in Q1 2023.
- Average Cash from Financing Activities over 5 years is $14.8 million, with a median of $374000.0 recorded in 2023.
- Year-over-year, Cash from Financing Activities soared 369080.95% in 2022 and tumbled 3440.0% in 2023.
- Tracing TNYA's Cash from Financing Activities over 5 years: stood at $77.5 million in 2022, then plunged by 99.52% to $371000.0 in 2023, then advanced by 1.62% to $377000.0 in 2024, then surged by 15348.81% to $58.2 million in 2025, then slumped by 100.71% to -$415000.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$415000.0 (Q1 2026), $58.2 million (Q4 2025), and $380000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Tenaya Therapeutics | 193.57 Mn | 193.57 Mn | - | -415,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -415,000.00 |
| Mar 31, 2026 | -415,000.00 |
| Dec 31, 2025 | 58.24 Mn |
| Dec 31, 2025 | 58.24 Mn |
| Sep 30, 2025 | 380,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | -476,000.00 |
| Jun 30, 2025 | -476,000.00 |
| Mar 31, 2025 | 50.26 Mn |
| Mar 31, 2025 | 50.26 Mn |
| Dec 31, 2024 | 377,000.00 |
| Dec 31, 2024 | 377,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Sep 30, 2024 | 31,000.00 |
| Jun 30, 2024 | 570,000.00 |
| Jun 30, 2024 | 570,000.00 |
| Mar 31, 2024 | 46.77 Mn |
| Mar 31, 2024 | 46.77 Mn |
| Dec 31, 2023 | 371,000.00 |
| Dec 31, 2023 | 371,000.00 |
| Jun 30, 2023 | 4.18 Mn |
| Jun 30, 2023 | 4.18 Mn |
| Mar 31, 2023 | -501,000.00 |
| Mar 31, 2023 | -501,000.00 |
| Dec 31, 2022 | 77.49 Mn |
| Dec 31, 2022 | 77.49 Mn |
| Sep 30, 2022 | 6,000.00 |
| Sep 30, 2022 | 6,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Sep 30, 2021 | 190.27 Mn |
| Sep 30, 2021 | 190.27 Mn |
| Jun 30, 2021 | -1.30 Mn |
| Jun 30, 2021 | -1.30 Mn |
| Mar 31, 2021 | 20.02 Mn |
| Mar 31, 2021 | 20.02 Mn |
| Dec 31, 2020 | 85.92 Mn |
| Dec 31, 2020 | 85.92 Mn |
| Sep 30, 2020 | 30.70 Mn |
| Sep 30, 2020 | 30.70 Mn |